ModernavsUnitedHealth

MRNA and UNH stock compared: price, dividend, valuation and results, from SEC filings.

MRNA

Moderna, Inc.

$194.01

Value $76.6B

-2.67%
MRNA's page

UNH

UnitedHealth Group Incorporated

$344.43

Value $313B

+4.22%
UNH's page

Moderna (MRNA) has a market value of $76.6B and UnitedHealth (UNH) $313B. Over the last year, with dividends, MRNA moved +702.4% and UNH +14.4%. Dividend yield: MRNA none, UNH 2.63%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRNA$76.6B

    UNH$313B

    UNH is 4.1 times MRNA

  • Revenue, 12 months

    MRNA$2.5B

    UNH$450B

    UNH is 178 times MRNA

  • Net income, 12 months

    MRNA-$2.8B

    UNH$15.9B

  • Operating margin

    MRNA-116.0%

    UNH5.3%

    121.3 points apart

  • ROIC

    MRNA-26.5%

    UNH11.3%

    37.8 points apart

  • P/E

    MRNA–

    UNH19.7

  • Dividend yield

    MRNA0.0%

    UNH2.6%

    2.6 points apart

  • 5-year return

    MRNA-26.5%

    UNH-14.3%

    12.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRNA-26.5%

UNH-14.3%

5010015020222023202420252026
Returns by period
PeriodMRNAWith dividendsUNHWith dividends
1 year since November 19, 2025+702.4%Price +702.4%+14.4%Price +11.4%
3 years since November 20, 2023+145.7%+34.9% a yearPrice +145.7%-31.4%-11.8% a yearPrice -35.6%
5 years since November 19, 2021-26.5%-6.0% a yearPrice -26.5%-14.3%-3.0% a yearPrice -21.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRNAModernaUNHUnitedHealth

Valuation

MRNAUNH
Valuation
Price$194.01$344.43
Market value$76.6B$313B
Enterprise value (EV)$74.4B$358B
P/E–19.7
P/E, 5-year median–25.0
P/B11.23.0
EV/EBIT–15.0
Free cash flow yield–7.3%

Results and growth

MRNAUNH
Results and growth
Revenue, 12 months$2.5B$450B
Net income, 12 months-$2.8B$15.9B
Free cash flow, 12 months-$2.0B$22.8B
Earnings per share, 12 months-$7.10$17.52
Revenue growth, year on year-39.9%11.8%
Revenue growth a year, past+19.3%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

MRNAUNH
Margins and returns on capital
Gross margin28.0%88.3%
Operating margin-116.0%5.3%
Net margin-110.5%3.5%
ROIC-26.5%11.3%
ROE-35.8%15.5%

Balance sheet

MRNAUNH
Balance sheet
Cash$5.2B$28.5B
Total debt$3.6B$74.3B
Net debt / EBITDA–1.6
Interest cover–6.2×

Dividends and buybacks

MRNAUNH
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield0.0%1.8%
Shareholder yield–4.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRNA or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Moderna or UnitedHealth?

By market value, UnitedHealth ($313B) is about 4.1 times Moderna ($76.6B), at today's prices.

How did MRNA and UNH stock do over the last 5 years?

Since November 19, 2021, MRNA's price moved -26.5% and UNH's -21.7%. With dividends: MRNA -26.5% (-6.0% a year), UNH -14.3% (-3.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRNA or UNH?

The dividend yield at today's price is none for Moderna and 2.63% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Moderna or UnitedHealth?

Over the last twelve months, the net margin was -110.5% for Moderna and 3.5% for UnitedHealth, and the operating margin -116.0% and 5.3%. Revenue was $2.5B and $450B.

Which is the better investment, Moderna or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.